» Articles » PMID: 12359124

Structural Basis of Fabry Disease

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2002 Oct 3
PMID 12359124
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Fabry disease is a lysosomal storage disease caused by deficiency in the enzyme alpha-galactosidase (alpha-GAL). To understand the molecular defects responsible for Fabry disease, we have collected more than 190 reported point and stop mutations and mapped them onto a model of human alpha-GAL based on the X-ray structure of the closely related enzyme alpha-N-acetylgalactosaminidase (alpha-NAGAL). The locations of the human alpha-GAL point mutations reveal two major classes of Fabry disease protein defects: active site mutations and folding mutations. Active site mutations reduce enzymatic activity by perturbing the active site without necessarily affecting the overall alpha-GAL structure. Folding mutations reduce the stability of alpha-GAL by disrupting its hydrophobic core. Examining the frequency of mutation around each alpha-GAL residue identifies the active site as a hotspot for mutations leading to Fabry disease. This study furthers our understanding of the structural basis for mutations leading to Fabry disease, from which new avenues for the treatment of lysosomal storage diseases may be developed.

Citing Articles

Fabry disease caused by the () variant: Clinical profile of a serious phenotype.

Liu Z, Wang Q, Yang D, Mao K, Wu G, Wei X Mol Genet Metab Rep. 2024; 40:101102.

PMID: 38911695 PMC: 11190550. DOI: 10.1016/j.ymgmr.2024.101102.


Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family.

Peng Y, Pan M, Wang Y, Shen Z, Xu J, Xiong F Ren Fail. 2024; 46(2):2362391.

PMID: 38847497 PMC: 11164125. DOI: 10.1080/0886022X.2024.2362391.


Fabry disease in W162C mutation: a case report of two patients and a review of literature.

Furia A, Ditaranto R, Biagini E, Parisi V, Incensi A, Parisini S BMC Neurol. 2024; 24(1):113.

PMID: 38580906 PMC: 10996216. DOI: 10.1186/s12883-024-03540-3.


characterization of cells derived from a patient with the variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease.

Breyer M, Gruner J, Klein A, Finke L, Klug K, Sauer M Mol Genet Metab Rep. 2024; 38:101029.

PMID: 38469097 PMC: 10926200. DOI: 10.1016/j.ymgmr.2023.101029.


Population Frequency of Undiagnosed Fabry Disease in the General Population.

Kermond-Marino A, Weng A, Xi Zhang S, Tran Z, Huang M, Savige J Kidney Int Rep. 2023; 8(7):1373-1379.

PMID: 37441486 PMC: 10334396. DOI: 10.1016/j.ekir.2023.04.009.